Description
Saypha Dermal Filler with Lido – HA Injectable for Wrinkle Correction and Volume
Saypha® Dermal Filler with Lido is a class of injectable hyaluronic acid (HA) dermal filler medical device formulated with high-concentration, cross-linked sodium hyaluronate and 0.3 % lidocaine hydrochloride to enhance patient comfort during injection. The HA is of non-animal origin and manufactured using advanced viscoelastic technology to produce a smooth, elastic gel suitable for soft tissue augmentation and wrinkle correction. It is indicated primarily for the correction of moderate to severe facial wrinkles, folds and lines, and for augmentation of lip volume and contouring. The integrated lidocaine reduces procedural discomfort and facilitates a more comfortable treatment experience for patients.
The gel is intended for injection into the mid to deep dermis or submucosal layer depending on the treatment area. Once placed, the HA binds to tissue water, restoring volume and improving skin smoothness while providing structural support to aging skin. The viscoelastic properties enable even distribution and natural-looking outcomes when administered by qualified professionals.
What Saypha Dermal Filler with Lidocaine Is Similar To
Saypha Dermal Filler with Lido can be regarded alongside other hyaluronic acid dermal fillers with lidocaine, such as Restylane® with Lidocaine or Juvederm® Ultra with Lidocaine, in that all use cross-linked HA to add volume, correct moderate to severe wrinkles, and improve facial contours. All these products contain a local anesthetic to improve comfort during injection.
Unlike skin-booster or bioremodelling products such as Profhilo® H+L — which are designed primarily for hydration and tissue quality with minimal volumetric lifting — Saypha Dermal Filler with Lido emphasises volume augmentation and wrinkle correction in targeted facial areas. Hyaluronic acid fillers with higher cross-linking are generally formulated to resist enzymatic degradation longer than non-cross-linked HA boosters, providing structural support as well as hydration. This comparison is provided for clinical orientation only and does not imply interchangeability.
Treatment Areas / Indications
According to manufacturer and distributor information, Saypha Dermal Filler with Lido is indicated for the following:
-
Correction of moderate to severe facial wrinkles, folds and lines, including nasolabial folds, marionette lines, glabellar lines and perioral wrinkles.
-
Lip augmentation and contouring to enhance volume and shape.
Treatment areas are consistent with typical hyaluronic acid dermal fillers and are determined by clinical need and practitioner assessment.
Usage / Administration (IFU-Only)
-
Injection depth: Mid to deep dermis; submucosa for lip augmentation.
-
Volume per injection site: Not provided by manufacturer.
-
Needle gauge: Two 27 G × ½″ (thin wall) sterile needles supplied with the syringe.
-
Frequency / number of sessions: Not provided by manufacturer.
-
Professional-use disclaimer: Administered only by qualified medical professionals trained in aesthetic injectable techniques and aseptic procedures.
If any parameter is omitted in the official IFU, it is recorded as “not provided by manufacturer.”
Ingredient List
-
Cross-linked hyaluronic acid (23 mg/mL).
-
Lidocaine hydrochloride (0.3 %).
-
Phosphate buffer and sodium chloride (physiologic buffer).
This formulation uses non-animal sourced HA with BDDE cross-linking to provide viscoelastic structure and durability.
Presentation & Longevity
-
Presentation: 1 × 1.0 mL pre-filled sterile syringe supplied with two 27 G × ½″ needles (CE 0197 traceable).
-
Shelf life: Not specified in public documentation; refer to product packaging for expiry date.
-
Longevity: Results are typically observed for up to approximately 9 months, although individual outcomes depend on patient metabolism, injection technique and treated area.
Safety Notes / Contraindications
Use is contraindicated in patients with known hypersensitivity to any component of the product, including hyaluronic acid or lidocaine. Avoid injecting into areas with active skin infection or inflammation until the condition resolves. Do not inject intravenously or into non-target tissues. As with other dermal fillers, strict aseptic technique and anatomical knowledge are essential to minimise risks of vascular occlusion or adverse tissue reactions. Purposes beyond the indicated facial areas should be assessed on a case-by-case basis.
Regulatory Status
Saypha Dermal Filler with Lido is a CE-marked medical device in the European Union under the Medical Device Regulation (MDR). Specific UKCA listings should be verified via the official Instructions for Use or authorised distributor documentation.
FAQ
1. How does Saypha Dermal Filler with Lido work?
Saypha Dermal Filler with Lido is a viscoelastic gel of cross-linked hyaluronic acid that binds water molecules in the dermis to restore volume and soften facial wrinkles and folds. The incorporated lidocaine (0.3 %) acts as a local anaesthetic to help reduce procedural discomfort during injection.
2. What distinguishes Saypha Filler from skin-booster products?
Unlike skin boosters or bioremodelling injectables that focus on diffuse hydration and tissue quality improvement, Saypha Filler is formulated as a volumetric dermal filler intended to correct discrete folds and restore contour in specific facial regions.
3. Where is Saypha Filler typically injected?
The product is intended for injection into the mid to deep dermis for wrinkle correction and into the submucosa for lip volume enhancement. Precise depth and injection technique should be determined by a qualified practitioner based on area and indication.
4. How long do results last?
Clinical experience and distributor information suggest that visible effects can last up to approximately 9 months, though this varies with patient metabolism, treatment site, and injection technique.
5. Is Saypha Filler suitable for everyone?
As with all injectable medical devices, use is contraindicated in patients with known hypersensitivity to any component or in the presence of active infection at the injection site. Treatment should be administered only by qualified medical professionals with appropriate anatomical training.
